Stemming the COVID-19 Pandemic

t Johnson & Johnson, we believe it is our responsibility to protect people, especially the most vulnerable, from the world’s most challenging and wide-reaching infectious diseases like COVID-19. That’s why from the very beginning, we have taken a stand against COVID-19 on a global scale. We have an enduring track record of tackling the world’s greatest health challenges, from tuberculosis to Ebola to HIV, with innovative solutions. We have done it before, and we will do it again.

Vaccines have been a critical component in tackling the COVID-19 pandemic. Our vaccine development technology, scientific expertise and global manufacturing capabilities provided a foundation to develop a vaccine candidate and upscale production so that we can get it in the hands of those who need it most, as quickly and as safely as possible. Vaccines like ours are playing a crucial role in preventing severe disease, hospitalizations and deaths, protecting hundreds of millions of people from serious and fatal outcomes of COVID-19. The Johnson & Johnson COVID-19 vaccine is an important choice for people who can’t or won’t return for multiple vaccinations or who would remain unvaccinated without an alternative, and aligns with the World Health Organization’s (WHO) recommendations for medical interventions in a pandemic setting, which emphasize ease of distribution, administration, and compliance.

Our commitment to families around the world doesn’t change in a time of crisis: we’ll never stop taking care of you.

Please note that by clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.

Find the status of Johnson & Johnson’s COVID-19 vaccine in countries around the world.

Learn More

Our Commitment to Scientific Excellence

Alongside other biopharmaceutical companies, we pledged to conduct our clinical research for a potential vaccine for COVID-19 in accordance with high ethical standards and sound scientific principles. Further, our COVID-19 clinical trials, and the development of all investigational products across Johnson & Johnson, are guided by protocols and standards that help ensure our trials are conducted professionally, ethically, and responsibly.

We invite you to learn more about our studies evaluating the safety and effectiveness of our COVID-19 vaccine, as well as our commitment to inclusivity, safety and transparency in our research.

Leveraging Janssen's AdVac® Technology

Leveraging Janssen's AdVac® Technology

Learn More
Information on the Studies Examining our COVID-19 Vaccine

Resources for COVID-19 Vaccine Education

Learn how we’re partnering with organizations to share trusted information about vaccines to promote acceptance worldwide.

Learn More

Hear From Our Leadership

At Johnson & Johnson, we believe in using our size and reach for good. We are proud to deliver a vaccine that can help protect people against COVID-19. We have a long legacy of fighting health crises, providing solutions that reach all corners of the world, and remain dedicated to our mission of improving health for everyone, everywhere.

— Joaquin Duato, Chief Executive Officer

Improving vaccine confidence is an essential step towards overcoming COVID-19 as vaccines become available for distribution. As hesitancy around vaccination remains, education is one of the most powerful ways we can allay lingering fears and increase understanding and trust in the science.

— Vanessa Broadhurst, Executive Vice President, Global Corporate Affairs

There is still much to be done to keep people safe from some of the most devastating impacts of COVID-19. Employing all available resources, including vaccination, helps prevent COVID-19-associated illness, hospitalization and deaths.

— Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Pharmaceuticals R&D

Since the start of the COVID-19 pandemic, we have been living with fear that we or our loved ones could become very ill, and in some cases so ill that we could be hospitalized or succumb to COVID-19. Johnson & Johnson has committed the full strength of our resources to create a solution to help combat the historic COVID-19 pandemic.

— Mathai Mammen, M.D., Ph.D., Executive Vice President, Pharmaceuticals, R&D

Latest News

March 08, 2022

Johnson & Johnson Announces Landmark Agreement to Enable its COVID-19 Vaccine to be Manufactured and Made Available by an African Company for People Living in Africa

Innovation

January 06, 2022

Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States

Innovation

December 30, 2022

Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant

Innovation

December 15, 2021

Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine

Innovation

December 09, 2021

World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster

Innovation

December 05, 2021

Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses

See All News

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, the Janssen COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 18 years of age and older for whom other FDA-authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and in individuals 18 years of age and older who elect to receive the Janssen COVID19 Vaccine because they would otherwise not receive a COVID-19 vaccine.